+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Opiate Receptor Subtype Regulation of CRF-41 Release from Rat Hypothalamus in vitro

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We have previously shown that the release of corticotrophin-releasing factor 41 (CRF-41) induced by a variety of neurotransmitters and depolarizing agents from the rat hypothalamus in vitro is inhibited by morphine. In order to further characterize the opiate receptors mediating this inhibitory action, we have now investigated the effects of a variety of opioid compounds with relatively high selectivity for µ-, ĸ- and δ-opiate receptors on K<sup>+</sup>-stimulated CRF-41 release. The selective µ-opioid receptor agonist 202–250 inhibited K+-evoked CRF-41 release in a dose-dependent manner with a maximum inhibition of approximately 60% at 10<sup>–5</sup> M (p < 0.01), as did the K-selective agonists PD-117,302 and U-50,488, with a similar plateau in response of approximately 40% inhibition at 10<sup>–6</sup> M (p < 0.05). The effects of these agonists were specifically reversed by the µ- and K-receptor antagonists naloxone and MR2266, repectively, while the specific δ-receptor antagonist ICI 154,129 was ineffective. Both naloxone and MR2266 slightly but significantly increased the basal release of CRF-41. The δ-agonist D-Pen<sup>2,5</sup>-enkephalin was without significant effect in the same dose range. These data suggest that both µ- and K-receptors, but not δ-receptors, mediate the inhibitory effect of opiates on stimulated CRF-41 release from the rat hypothalamus.

          Related collections

          Author and article information

          S. Karger AG
          03 April 2008
          : 51
          : 5
          : 599-605
          Departments of aEndocrinology and bChemical Endocrinology, St. Bartholomew’s Hospital, London, UK
          125397 Neuroendocrinology 1990;51:599–605
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article